TickerFacts.

Apimeds Pharmaceuticals US, Inc. (APUS): R&D Expense

Annual figures by period end, from SEC filings.

$1.63M
Year ended 2025-12-31
$2.84M
Trailing 12 months to 2026-06-30
2023-12-31: $98.5K2025-12-31: $1.63M$1.63M
2023-12-31 R&D Expense (USD) 2025-12-31
Period endedR&D ExpenseChange YoYSource filing
2025-12-31$1.63Mn/a2026-05-04, From 2025-01-01
No annual figure between 2023-12-31 and 2025-12-31.
2023-12-31$98.5Kn/a2025-04-15, From 2023-01-01

R&D Expense at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedR&D ExpenseChange YoY
Apimeds Pharmaceuticals US, Inc. (APUS)2025-12-31$1.63Mn/a
Cypherpunk Technologies Inc. (CYPH)2025-12-31$25.67M-55.1%
Transcode Therapeutics, Inc. (RNAZ)2025-12-31$13.42M+38.3%
Gyre Therapeutics, Inc. (GYRE)2025-12-31$13.70M+13.9%
Climb Bio, Inc. (CLYM)2025-12-31$46.71M+225.8%
Aclaris Therapeutics, Inc. (ACRS)2025-12-31$52.65M+56.7%
Aquestive Therapeutics, Inc. (AQST)2025-12-31$17.19M-15.2%
Corbus Pharmaceuticals Holdings, Inc. (CRBP)2025-12-31$70.09M+117.5%
Eledon Pharmaceuticals, Inc. (ELDN)2025-12-31$66.27M+27.5%

Compare APUS, CYPH, RNAZ, GYRE side by side · Screen every company in Pharmaceutical Preparations ↗